Dr. Nadeem on Individualizing Therapy in Multiple Myeloma

Omar Nadeem, MD
Published: Wednesday, Jul 24, 2019



Omar Nadeem, MD, a physician at Dana-Farber Cancer Institute and an instructor in medicine at Harvard Medical School, discusses individualizing therapy for patients with multiple myeloma.

As more therapies become available, more thought will have to be put into determining how best to sequence agents. In the relapsed setting, that will be the most important aspect of treatment, says Nadeem. If 4-drug regimens are adopted into the frontline setting, their impact on subsequent exposure to later lines of therapy and current standards of care, such as stem cell transplantation, will need to be assessed.

Escalation and de-escalation of therapy is another component of individualizing treatment. As such, tools are needed that will alert providers to when a patient who begins intensive therapy can de-escalate their treatment. These questions have never been truly asked before, says Nadeem. Over time, more medications and tools will be developed to individualize therapy for patients; this will be critical as no 2 patients with myeloma are alike, concludes Nadeem.
SELECTED
LANGUAGE


Omar Nadeem, MD, a physician at Dana-Farber Cancer Institute and an instructor in medicine at Harvard Medical School, discusses individualizing therapy for patients with multiple myeloma.

As more therapies become available, more thought will have to be put into determining how best to sequence agents. In the relapsed setting, that will be the most important aspect of treatment, says Nadeem. If 4-drug regimens are adopted into the frontline setting, their impact on subsequent exposure to later lines of therapy and current standards of care, such as stem cell transplantation, will need to be assessed.

Escalation and de-escalation of therapy is another component of individualizing treatment. As such, tools are needed that will alert providers to when a patient who begins intensive therapy can de-escalate their treatment. These questions have never been truly asked before, says Nadeem. Over time, more medications and tools will be developed to individualize therapy for patients; this will be critical as no 2 patients with myeloma are alike, concludes Nadeem.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication
x